Providing PEP/PrEP in the Pharmacy Setting:
A Comprehensive User Guide 2023

PrEP PHARMACY MONOGRAPH

Are you seeking specific insights and suggestions as you prepare to implement postexposure prophylaxis (PEP) and preexposure prophylaxis (PrEP) in your pharmacy practice? This activity qualifies participants for 2.0 CPE credits to fulfill State Board of Pharmacy training requirements.

Calling all pharmacists from Utah, Illinois, and Maine!

Your Board of Pharmacy has recently expanded your scope of practice to include prescribing and dispensing of PEP and PrEP. Learn the details specific to your state with these short primers:

	Providing PrEP in the Pharmacy Setting Utah Edition
	Providing PrEP in the Pharmacy Setting Illinois Edition
	COMING SOON: Providing PrEP in the Pharmacy Setting Maine Edition

___________________________________________________________________________________________

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Baeten JM, et al. N Engl J Med. 2012;367(5):399-410.

Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts.

Cahill S, et al. AIDS Care. 2017;29(11):1351-1358.

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Choopanya K, et al. Lancet. 2013;381(9883):2083-2090.

Assessing the efficacy and feasibility of a retail pharmacy-based HIV testing program.

Collins BC, et al. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 13-17, 2017; Seattle, WA. Abstract 962.

Community pharmacy delivered PrEP to STOP HIV transmission: an opportunity NOT to miss!

Lopez MI, et al. J Am Pharm Assoc (2003). 2020;60(4):e18-e24.

Why don’t patients take their drugs? The role of communication, context and culture in patient adherence and the work of the pharmacist in HIV/AIDS.

Penn C, et al. Patient Educ Couns. 2011;83(3):310-318.

4 findings from a successful HIV PrEP program.

Ross M. Pharm Times.

Drug database: emtricitabine/tenofovir alafenamide.

HIV.gov.  

Drug database: emtricitabine/tenofovir disoproxil fumarate.

HIV.gov.

Drug database: cabotegravir.

HIV.gov.

Being PrEPared—preexposure prophylaxis and HIV disparities.

Goldstein RH, et al. N Engl J Med. 2018;379(14):1293-1295.

Lifetime risk of a diagnosis of HIV infection in the United States.

Hess KL, et al. Ann Epidemiol. 2017;27(4):238-243.

Cabotegravir for HIV prevention in cisgender men and transgender women.

Landovitz RJ, et al; HPTN 083 Study Team. N Engl J Med. 2021;385(7):595-608.

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Mayer KH, et al. Lancet. 2020;396(10246):239-254.

Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care.

Tung EL, et al. Sex Health. 2018;15(6):556-561.

HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection.

Weidle PJ, et al. J Am Pharm Assoc (2003). 2014;54(5):486-492.

Patient Resources

HIV basics.

Centers for Disease Control and Prevention.

Prevention for women. Resources on HIV prevention for US women.

HIVE online.

HIV resources.

National Institutes of Health.

Positively Aware.

Positively Aware, created by TPAN (Test Positive Aware Network), is a source of HIV-treatment news for consumers, as well as an educational tool for HIV caregivers. The site features PrEP resources, including videos for men who have sex with men and transgender people.

UCSF transgender care.

University of California, San Francisco.